Indication
Urothelial Carcinoma Recurrent
5 clinical trials
7 products
Product
UGN-301Clinical trial
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBCStatus: Recruiting, Estimated PCD: 2025-12-01
Product
UGN-201Product
GemcitabineProduct
Bacillus Calmette-GuerinClinical trial
A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.Status: Not yet recruiting, Estimated PCD: 2025-12-30
Product
MitomycinClinical trial
uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With JelmytoStatus: Recruiting, Estimated PCD: 2025-04-01
Product
JelmytoClinical trial
Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk TumorsStatus: Recruiting, Estimated PCD: 2024-05-01
Product
Pemigatinib